News

Topical analgesics can help ease patients off of opioids, offering a ray of hope in the midst of a growing opioid addiction crisis.

Patients with ADHD have an increased risk of developing STIs later in life compared with the non-ADHD comparisons.

The FDA recently approved the therapy after showing reduction in patients' polyp grade, and reduction in sense of nasal obstruction and congestion.

On Tuesday, University of Central Florida (UCF) senior linebacker Shaquem Griffin became the 10th winner of the prestigious Rare Disease Champion Award.

The trial is the first head-to-head clinical comparison in ankylosing spondylitis investigating the superiority of secukinumab for slowing spinal bone damage versus proposed biosimilar adalimumab.

BioMarin Chief Executive Officer Jean-Jacques Bienaime spoke about the company’s development of valoctocogene roxaparvovec, a gene therapy in development for the treatment of Hemophilia A.

The study demonstrated proof-of-concept, demonstrating a sustained delivery system of 3 highly-potent antiretroviral therapies and drug-polymer matrices.

Global Blood Therapeutics, Inc. was granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for voxelotor for the treatment of sickle cell disease.

Adamas Pharmaceuticals, Inc. announced the full commercial launch of Gocovri (amantadine) extended release capsules for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

No significant differences were found between the non-impaired participants and the AD group regarding personality changes prior to onset.

Exercise for patients with PD has been shown to be effective, and for those in the early stages, high-intensity exercise can be beneficial.

Optical coherence tomography accrued savings of $9.0 billion for the US government through Medicare and an estimated $2.2 billion in savings for AMD patients since 2013.

The Senza II SCS System will deliver electrical pulse therapy to patients' spinal cords.

Acceleron Pharma has announced that Part 1 of the Phase 2 clinical trial of ACE-083, a drug used to increase muscle volume in facioscapulohumeral dystrophy (FSHD), has exhibited positive results.

Stephen Hawking, the notable British physicist and author of A Brief History of Time, celebrates his 76th birthday today, making him one of the longest surviving patients with amyotrophic lateral sclerosis (ALS).

The trial featured schoolchildren with persistent asthma from an urban region.

The Alder Pharmaceuticals product showed an average reduction of 8.2 monthly headache days.

Last week, Pfizer announced a new partnership with Sangamo. As part of the agreement, the sides will team to develop a potential gene therapy to treat ALS, or Lou Gehrig’s disease.

Clear or mostly clear skin was achieved by 50/31/14% of patients receiving 30/15/7.5 mg doses of upadacitinib, compared to 2% of patients receiving placebo.

Two months after Ionis submitted its NDA to the U.S. FDA, the company has announced that the regulatory agency has accepted its investigational drug inotersen for Priority Review.

The discovery fills a gap in lacking non-drug asthma therapies which health care providers can recommend to patients.

Dr. Ianchulev discusses his breakthrough technology, miLOOP, that will revolutionize the way cataract surgery is performed and how doctors fragment the lens.

Human factors determine the quality of environmental cleaning and remain the best defense against invisible threats.

Improvement in early screening, the development of biomarkers and therapy testing will change the screening process for autism and ADHD.

This morning, it was announced that Retrophin, Inc. and Censa Pharmaceuticals are partnering to continue development and evaluate CNSA-001 for the treatment of phenylketonuria (PKU).

Mallinckrodt plc has completed the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), as per an official announcement from the company yesterday.

Extended-pulsed fidaxomicin proved superior to standard vancomycin therapy for sustained clinical cure after 30 days.

Unapproved stem cell therapies now bring in $2.4 billion per year. The FDA is working to ensure they follow regulatory, safety and efficacy guidelines.

Last night, the U.S. FDA posted a warning letter addressed to American CryoStem Corporation for marketing an adipose derived stem cell product without FDA approval and for significant deviations from current good manufacturing practice requirements.